Posted by Michael Wonder on 05 May 2018
Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs
4 May 2018 - NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.
Two of the drugs, midostaurin, also known as Rydapt and arsenic trioxide or Trisenox are recommended for adults with certain types of leukaemia.
Meindert Boysen, director of the NICE centre for health technology evaluation, said “For the past 30 years, treatments for leukaemia have changed very little. With our positive recommendations for midostaurin and arsenic trioxide we are pleased to offer patients with leukaemia more treatments than ever before.”
